This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): EUR-1008, pancrelipase capsules, Zentase
Description: Zentase is a zero-overfill, orally delivered, porcine-derived pancreatic enzyme product consisting of approximately 14 enzymes, coenzymes and cofactors. It is biologically similar to endogenous human pancreatic secretions and is intended to treat malabsorption of fats, proteins, carbohydrates and other essential nutrients.
Samil and Eurand
In August 2009, Eurand announced that it signed a commercialization and supply agreement for ZENPEP in South Korea with Samil Pharmaceutical.
Axcan (now Aptalis) and Eurand
In December 2010, Eurand and Axcan entered into a definitive agreement under which Axcan will acquire all the outstanding shares of Eurand for $12.00 per share in cash. The fully diluted equity value of the transaction is approximately $583 million. The transaction closed in February 2011.
In May 2011, Axcan changed its name to Aptalis Pharma.
Nycomed (subsidiary of Takeda) and Eurand
In January 2011, Eurand entered into an exclusive commercialization, license and supply agreement with Nycomed for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial terms were not disclosed. Under the agreement, Nycomed Russia-CIS will market and distribute ZENPEP (pancrelipase) Delayed-Release Capsules in Russia and...See full deal structure in Biomedtracker
Partners: Samil Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: